TriangleNCT00003140 · CITED IN SOURCE DOCUMENTS
Letrozole After Tamoxifen in Treating Women With Breast Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2026-03-27
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed primary invasive breast carcinoma resected at time of original diagnosis * No ductal carcinoma in situ * Axillary lymph node negative, positive, or unknown * No evidence of metastases * No localized or distant breast cancer recurrence * Not registered on protocol NCCTG-893052, any other IBCSG protocol, or protocol SWOG-S9623 * Hormone receptor status: * Estrogen or progesterone receptor positive as defined by tumor receptor content at least 10 fmol/mg protein or receptor positive by ERICA or PgRICA * Unknown status allowed if effort to determine status has been made by immunocytochemistry * No contralateral breast cancer PATIENT CHARACTERISTICS: Age: * Postmenopausal Sex: * Female Menopausal status: * Postmenopausal defined by one of the following: * Age 50 or over at start of adjuvant tamoxifen * Under age 50 and considered postmenopausal by treating physician at start of adjuvant tamoxifen * Under age 50 at start of adjuvant tamoxifen and had bilateral oophorectomy (surgical or radiation) * Under age 50 and premenopausal at start of adjuvant tamoxifen, but became amenorrheic during tamoxifen and remained amenorrheic for at least 1 year * Considered postmenopausal by physician with LH/FSH levels under the treatment center's postmenopausal limits Performance status: * ECOG 0-2 Life expectancy: * At least 5 years Hematopoietic: * WBC ≥ 3,000/mm\^3 OR * Granulocyte count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 Hepatic: * AST and/or ALT \< 2 times upper limit of normal (ULN) (unless imaging examinations have ruled out metastatic disease) * Alkaline phosphatase \< 2 times ULN (unless imaging examinations have ruled out metastatic disease) Renal: * Not specified Other: * No concurrent medical or psychiatric condition that would preclude study participation * No other malignancy within the past 5 years except adequately treated superficial squamous cell or basal cell skin cancer or carcinoma in situ of the cervix * Able to swallow study drug * Adequate oral intake PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Prior adjuvant chemotherapy allowed * No concurrent chemotherapy Endocrine therapy: * Completed at least 4.5 but no more than 6 years of adjuvant tamoxifen after resection * Completed at least 4.5-6 years of adjuvant aromatase inhibitor as initial therapy or after tamoxifen * No more than 3 months since prior adjuvant tamoxifen * No concurrent hormone replacement therapy (e.g., megestrol) * No concurrent selective estrogen-receptor modulators (e.g., raloxifene or idoxifene) * Concurrent intermittent vaginal estrogens (e.g., Estring) allowed if other local measures for intractable vaginal atrophy are insufficient * No other concurrent aromatase inhibitors * No more than 2 years since prior aromatase inhibitor therapy (re-randomization) Radiotherapy: * Prior radiotherapy allowed Surgery: * See Disease Characteristics Other: * At least 1 month since prior investigational drugs * Prior treatment on a clinical trial for breast cancer allowed if permission has been obtained from the sponsors of the original study for their patient to participate on MA.17/JMA.17/BIG-97-01 * No prior placebo on core protocol * No concurrent anticancer therapy * Concurrent thyroid medication, calcium, vitamin D, and bisphosphonates allowed
- healthy Volunteers
- false
- maximum Age
- 120 Years
- minimum Age
- 0 Years
- sex
- FEMALE
- std Ages
- CHILD
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients receive oral letrozole once daily.
- intervention Names
- Drug: letrozole
- label
- Arm I
- type
- EXPERIMENTAL
- description
- Patients receive oral placebo once daily.
- intervention Names
- Other: placebo
- label
- Arm II
- type
- PLACEBO_COMPARATOR
- interventions
- arm Group Labels
- Arm I
- description
- Given orally
- name
- letrozole
- other Names
- Femara
- type
- DRUG
- arm Group Labels
- Arm II
- description
- Given orally
- name
- placebo
- type
- OTHER
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- TRIPLE
- who Masked
- PARTICIPANT
- INVESTIGATOR
- OUTCOMES_ASSESSOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 5187
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Disease-free survival
- time Frame
- 5 years
Full study description
- brief Summary
- RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
- detailed Description
- OBJECTIVES: Primary * Compare the disease-free survival and overall survival of postmenopausal women with primary breast cancer who have completed at least five years of adjuvant aromatase inhibitor as initial therapy or after tamoxifen treated with letrozole or placebo. Secondary * Compare the incidence of contralateral breast cancer in patients treated with these regimens. * Evaluate the long-term clinical and laboratory safety of letrozole, in terms of lipid profile, cardiovascular morbidity and mortality, incidence of bone fractures, change in bone density, and common toxic effects, in this patient population. * Compare the quality of life of patients treated with these regimens. Re-randomization Primary * Compare disease-free survival of patients who, after receiving at least 4.5 years of letrozole, are re-randomized to receive an additional 5 years of letrozole vs placebo. Secondary * Determine whether common genetic polymorphisms for genes encoding proteins involved in pharmacokinetic and/or pharmacodynamic pathways for letrozole contribute to individual variation in toxicity and efficacy of letrozole therapy. OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to receptor status (positive vs unknown), lymph node status (negative vs positive vs unknown), prior adjuvant chemotherapy (yes vs no), interval between last dose of aromatase inhibitor therapy and randomization (\< 6 months vs 6 months-2 years), and duration of prior tamoxifen use (0 years vs \< 2 years vs 2-4.5 years vs \> 4.5 years). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral letrozole once daily. * Arm II: Patients receive oral placebo once daily. In both arms, treatment continues for 5 years in the absence of disease progression or unacceptable toxicity. Patients in arm II may then be offered oral letrozole once daily for up to 5 years. Quality of life is assessed at baseline, at 6 months, and then annually for 4.5 years. * Double-blind, re-randomization: Patients who complete ≥ 4.5 years of letrozole (arm I) and who did not experience recurrent disease or new primary breast cancer, including ductal carcinoma in situ, may participate in the double-blind, placebo-controlled, re-randomization portion of the study. Patients are stratified according to lymph node status at enrollment (negative vs positive vs unknown), prior adjuvant chemotherapy (yes vs no), and interval between last dose of letrozole and re-randomization (\<6 months vs 6 months to 2 years). Common genetic single nucleotide polymorphisms for genes encoding proteins involved in pharmacokinetic and/or pharmacodynamic pathways for letrozole are analyzed in order to determine if these single nucleotide polymorphisms contribute to individual variation in toxicity and efficacy of letrozole therapy. Quality of life is assessed as during the first randomization. Patients are followed annually. PROJECTED ACCRUAL: A total of 4,700 patients will be accrued for this study.
Source references
- references
- citation
- Baum M. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now? Eur J Cancer. 2005 Aug;41(12):1667-77. doi: 10.1016/j.ejca.2005.05.006.
- pmid
- 16046117
- type
- BACKGROUND
- citation
- Baum M. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control. 2004 Jul-Aug;11(4):217-21. doi: 10.1177/107327480401100402.
- pmid
- 15284712
- type
- BACKGROUND
- citation
- Booth CM, Pater JL, Goss PE. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen. Cancer. 2007 May 1;109(9):1927-8; author reply 1928. doi: 10.1002/cncr.22613. No abstract available.
- pmid
- 17354227
- type
- BACKGROUND
- citation
- Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin. 2006 Aug;22(8):1575-85. doi: 10.1185/030079906X120940.
- pmid
- 16870082
- type
- BACKGROUND
- citation
- Scott LJ, Keam SJ. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer. Drugs. 2006;66(3):353-62. doi: 10.2165/00003495-200666030-00010.
- pmid
- 16526826
- type
- BACKGROUND
- citation
- Vakaet L. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2006 Aug 16;98(16):1162; author reply 1162-3. doi: 10.1093/jnci/djj323. No abstract available.
- pmid
- 16912269
- type
- BACKGROUND
- citation
- Wardley AM. Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. Clin Breast Cancer. 2006 Feb;6 Suppl 2:S45-50. doi: 10.3816/cbc.2006.s.003.
- pmid
- 16595026
- type
- BACKGROUND
- citation
- Goss PE, Ingle JN, Martino S, et al.: Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-13, 2009.
- type
- RESULT
- citation
- Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20;26(12):1948-55. doi: 10.1200/JCO.2007.11.6798. Epub 2008 Mar 10.
- pmid
- 18332475
- type
- RESULT
- citation
- Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol. 2008 May;19(5):877-82. doi: 10.1093/annonc/mdm566. Epub 2008 Mar 10.
- pmid
- 18332043
- type
- RESULT
- citation
- Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008 Apr 20;26(12):1956-64. doi: 10.1200/JCO.2007.12.6334. Epub 2008 Mar 10.
- pmid
- 18332474
- type
- RESULT
- citation
- Chapman JW, Meng D, Shepherd L, et al.: Competing causes of death in breast cancer extended adjuvant endocrine therapy: NCIC CTG MA.17. [Abstract] American Society of Clinical Oncology 2007 Breast Cancer Symposium, 7-8 September 2007, San Francisco, California A-56, 2007.
- type
- RESULT
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-d0e347509940bd8b1b2b
- requested nct id
- NCT00003140
- primary nct id
- NCT00003140
- source kind
- fda_spl_label
- source record id
- 28456311-e797-457f-8a9e-54dca5a7a336
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- cf2b000df8ec5845edfa108f58440f5a6a647a1ff17bf7e24572ca4078c104d8
- payload
- application numbers
- NDA020726
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-d0e347509940bd8b1b2b
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00003140
- occurrences
- context exact
- s. 14.2 Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 Months A double-blind, randomized, placebo-controlled trial (MA-17, NCT00003140) of Femara was performed in over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who were disease free after 5 years of adju
- end
- 8350
- exact text
- NCT00003140
- start
- 8339
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/44/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 28456311-e797-457f-8a9e-54dca5a7a336
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 57f38d94e47f3b39b17b5386e2c60c4ebba3a250ae84c9871ce91644af32f09a
- spl effective time
- 20260611
- spl set id
- 82b77d74-085f-45ac-a7dd-1f5c038bf406
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e087c84f44a854a50d25
- requested nct id
- NCT00003140
- primary nct id
- NCT00003140
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- payload sha256
- b656a38023cb104ecb3a496b6c80fb17447a0c26a7463dd6e6952f5ee2a30f35
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e087c84f44a854a50d25
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00003140
- occurrences
- context exact
- ping tamoxifen at that time.</p> <div class="pdq-content-list"><ol id="_3430"><li>A large, double-blinded, randomized trial (<a href="/clinicaltrials/NCT00003140">CAN-NCIC-MA17</a> [NCT00003140]) of 5,187 patients compared the use of letrozole versus placebo in receptor-positive postmenopausal women who received tamox
- end
- 351777
- exact text
- NCT00003140
- start
- 351766
- context exact
- <div class="pdq-content-list"><ol id="_3430"><li>A large, double-blinded, randomized trial (<a href="/clinicaltrials/NCT00003140">CAN-NCIC-MA17</a> [NCT00003140]) of 5,187 patients compared the use of letrozole versus placebo in receptor-positive postmenopausal women who received tamoxifen for approximately 5 years
- end
- 351809
- exact text
- NCT00003140
- start
- 351798
- context exact
- that was designed to compare 5 years of exemestane with placebo after 5 years of tamoxifen was stopped prematurely when the results of <a href="/clinicaltrials/NCT00003140">CAN-NCIC-MA17</a> became available. At the time of analysis, 560 of the 783 patients who were randomly assigned to receive exemestane remained on that drug an
- end
- 353979
- exact text
- NCT00003140
- start
- 353968
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/29bf1e5a1d739974ed.html
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:35.419733+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 536430925e3b0008edd3fb69a869d5645bd6b6dc5c84c21ddf1b3e24f089874c
- source title
- Breast Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: April 25, 2025
- datetime
- 2025-04-25T12:00:00Z
- display
- April 25, 2025
Preserved source evidence · Not medical advice